Literature DB >> 21225102

What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

Ingo Ahrens1, Gregory Y H Lip, Karlheinz Peter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21225102     DOI： 10.1160/TH10-12-0808

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  11 in total

1.  Hotline update of clinical trials and registries presented at the 77th spring meeting of the German Society of Cardiology 2011.

Authors:  J M Sinning; K Walenta; N Werner; M Böhm
Journal:  Clin Res Cardiol       Date:  2011-06-09       Impact factor: 5.460

Review 2.  The management of stroke in antiphospholipid syndrome.

Authors:  Kessarin Panichpisal; Eduard Rozner; Steven R Levine
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 3.  Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants.

Authors:  Konstantina Mitrousi; Gregory Y H Lip; Stavros Apostolakis
Journal:  J Atr Fibrillation       Date:  2013-06-30

4.  The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia.

Authors:  Yutao Guo; Gregory Y H Lip; Stavros Apostolakis
Journal:  Malays J Med Sci       Date:  2012-07

5.  Medical management of venous thromboembolism: what the interventional radiologist needs to know.

Authors:  Raj S Kasthuri; Nigel S Key
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

Review 6.  Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.

Authors:  Charalampos Kasmeridis; Stavros Apostolakis; Lars Ehlers; Lars H Rasmussen; Giuseppe Boriani; Gregory Y H Lip
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

7.  Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk.

Authors:  Andreas Charidimou; Clare Shakeshaft; David J Werring
Journal:  Front Neurol       Date:  2012-09-19       Impact factor: 4.003

8.  Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?

Authors:  Tahmeed Contractor; Atul Khasnis
Journal:  Cardiol Res Pract       Date:  2011-03-30       Impact factor: 1.866

9.  Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

Authors:  Joshua Pink; Steven Lane; Munir Pirmohamed; Dyfrig A Hughes
Journal:  BMJ       Date:  2011-10-31

10.  Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation.

Authors:  Jean-Christophe Lega; Laurent Bertoletti; Cyrielle Gremillet; Céline Chapelle; Patrick Mismetti; Michel Cucherat; Denis Vital-Durand; Silvy Laporte
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.